Key Highlights

  • Deborah Waterhouse was named as CSL’s next chief executive and managing director, starting from February.
  • FY26 Revenue was US$15.8 billion, down 1 per cent.
  • Underlying net profit after tax and Amortisation was US$3.1 billion, down 2 per cent.
  • Management guided to underlying net profit growth of about 5 per cent for FY27.

CSL Limited, a member of the S&P/ASX 50, announced on 21 October 2026 that Deborah Waterhouse, currently chief executive of ViiV Healthcare, will become its next chief executive and managing director from February.

It is too early to say whether Leadership alone will alter the company's trajectory, and the financial evidence below shows why caution is reasonable.

What CSL does

CSL is a global biotechnology group built around three businesses. CSL Behring makes plasma-derived and recombinant therapies, including immunoglobulins, albumin and haemophilia products. CSL Seqirus supplies influenza vaccines. CSL Vifor focuses on iron deficiency and nephrology treatments.

Latest developments

On 18 August 2026 CSL reported results for the year to 30 June 2026, which its interim chief executive, Gordon Naylor, described as a year of reset. The company also announced a new buyback of US$1.1 billion after completing an earlier A$1 billion programme.

On 21 October 2026 the board named Ms Waterhouse as successor to Mr Naylor. She previously led GSK's United States vaccines and primary care businesses and was its general manager for Australia and New Zealand from 2008 to 2012.

Financial and operational evidence

For the year to 30 June 2026, revenue was US$15.8 billion, down 1 per cent. Underlying net profit after tax and amortisation was US$3.1 billion, down 2 per cent, and Operating Cash Flow was US$3.5 billion. Reported results showed a net loss of US$2.6 billion, reflecting pre-tax impairments of US$7.1 billion and one-off restructuring costs of US$799 million. Transformation savings of about US$176 million were reported. The final Dividend was US$1.62, and the annual dividend of US$2.92 matched the prior year.

By segment, CSL Behring revenue fell 1 per cent to US$11.4 billion. Immunoglobulin sales were flat at US$6.25 billion, although the second half grew 7 per cent. Albumin fell 17 per cent on Chinese government cost controls. CSL Vifor revenue rose 3 per cent, but iron sales fell 16 per cent on generic competition. CSL Seqirus revenue fell 8 per cent to US$2 billion, partly because the prior year included non-recurring avian influenza revenue.

For the 2027 financial year, management guided to revenue in line with the previous year and underlying net profit growth of about 5 per cent. It expects Behring to deliver mid-single-digit revenue growth, Seqirus low single-digit growth and Vifor revenue to fall by about 25 per cent.

Material risks

Further write-downs cannot be ruled out if conditions deteriorate.

Vifor faces generic competition and regulatory change, and guidance implies a steep revenue decline there. Seqirus depends on vaccination rates, and management flagged softer United States immunisation. Albumin remains exposed to pricing policy in China.

Guidance carries execution risk, particularly the expected recovery in immunoglobulin growth and the delivery of plasma capacity expansion. A change of chief executive in February adds transition risk, and the company has operated under an interim leader. Shareholder litigation relating to earlier guidance revisions has also been reported.

Milestones to watch

Investors will be watching for Ms Waterhouse's arrival in February and any early strategic priorities she outlines. The half-year result, expected in February 2027, should show whether immunoglobulin growth and cost savings are tracking guidance. Other markers include the new buyback, Seqirus performance through the Northern Hemisphere influenza season, and any further impairments or portfolio decisions.